ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Consequently, selective interference with BCR‐ABL1 mRNA (Figure 1D) will ensure therapeutic intervention only in CML cells, substantially reducing the potential for side effects and adverse events.